BioLoomics

BioLoomics is a preclinical-stage biotechnology company that is pioneering the use of human cells for the directed evolution of target-degrading antibodies. Initiated by a founding team rooted in DARPA’s Rapid Threat Assessment (RTA) program, BioLoomics combines expertise in robotics, synthetic biology, and machine learning. Using a blend of synthetic biology and computer vision-guided cell picking, its technology can efficiently navigate the antibody design space to discover designs that leverage novel mechanisms for target degradation.